Angiogenesis is closely associated with tumorigenesis, progression, metastasis, and prognosis of lung cancer. This also include neovascularization with unrestricted proliferation of tumor cells. In addition, anti-angiogenic monotherapy has limited clinical efficacy, and drug resistance is evident. As a result, the "A+A" strategy (the combination of two or more anti-angiogenic medications targeting various angiogenic signaling pathways) is thought to achieve more potent anti-tumor effects. Avastin and Erlotinib, for example, were recently approved for the treatment of NSCLC with EGFR-activating mutations, and the results were verified by a phase III clinical trial (NEJ026).

At present, GemPharmatech' extensive collection possesses 6 cases of PDX tumor samples of Lung Cancer.